Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

27.90 -39.79 (-58.78%)
Streaming Delayed Price Updated: 9:45 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Shares of uniQure Are Dropping Tuesday
The company is facing being delisted from the S&P 600 Index. 
Via The Motley Fool
Topics Stocks
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
Clinical trial initiation expected in the fourth quarter of 2023 
From uniQure Inc.
Via GlobeNewswire
Airbnb, Blackstone Rise On News They'll Join S&P 500 Index
ABNB and BX will join Sept. 18 as part of a quarterly rebalancing. 
Via Investor's Business Daily
Topics Stocks
Analyst Expectations for uniQure's Future
 
Via Benzinga
Why uniQure Stock Cratered This Week
An interim analysis for the company's Huntington's disease gene therapy wasn't a hit with investors. 
Via The Motley Fool
3 Tantalizing Stocks to Buy for Under $10
While investors should stick with the predictable ideas, those that want robust returns should target these stocks under $10 to buy. 
Via InvestorPlace
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  During Thursday, 56 stocks hit new 52-week lows. 
Via Benzinga
Chardan Capital Maintains Buy Rating for uniQure: Here's What You Need To Know
 
Via Benzinga
Why UniQure Stock Is Trading Down Today
UniQure N.V. (NASDAQ: QURE) shares are lower after the company announced interim data from the Phase I/II trial of AMT-130 in Huntington's Disease. 
Via Benzinga
Where uniQure Stands With Analysts
 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
Why uniQure Stock Is Crashing Today
Investors are focusing on the negative parts of the biotech company's interim results. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 54 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 40 stocks hit new 52-week lows. 
Via Benzinga
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
~ Walid Abi-Saab, M.D., appointed Chief Medical Officer, will bring extensive track record in leading drug development and execution ~ 
From uniQure Inc.
Via GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Nordson To Rally Over 14%? Here Are 10 Other Analyst Forecasts For Thursday
Chardan Capital cut the price target for uniQure N.V. (NASDAQ: QURE) from $45 to $27. Chardan Capital analyst Matthew Barcus maintained a Buy rating. uniQure shares fell 1.5% to $11.45 in pre-market... 
Via Benzinga
Crude Oil Rises 2%; LumiraDx Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with Nasdaq Composite dropping over 100 points on Wednesday. The Dow traded down 0.04% to 34,040.13 while the NASDAQ fell 0.77% to 13,562.00. The S&P... 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why ToughBuilt Industries Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 209.5% to $2.29 after the company signed a Letter of Intention with UAE-Based e-script medicine management company Pharmak... 
Via Benzinga
Nasdaq Tumbles 1%; Patterson Companies Earnings Beat Views
U.S. stocks traded mostly lower midway through trading, with Nasdaq Composite dropping over 100 points on Wednesday. 
Via Benzinga
Uniqure Crashes To Six-Year Low On Muddy Results For Huntington's Gene Therapy
The company is working on a one-time treatment for Huntington's disease. 
Via Investor's Business Daily
Dow Drops Over 100 Points; Winnebago Industries Posts Downbeat Sales
U.S. stocks traded lower this morning, with Dow Jones dropping over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.41% to 33,914.60 while the NASDAQ fell 0.31%... 
Via Benzinga
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL Behring 
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
uniQure's Hemgenix Royalty Sales Agreement Extends Cash Runway, Relieves Near-Term Commercial Risk, Says Analyst
uniQure N.V. (NASDAQ: QURE) agreed to sell a portion of the royalty rights due from CSL Behring from Hemgenix (etranacogene dezaparvovec-drbl) net sales to HealthCare Royalty and Sagard Healthcare  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.